Marianna Koczywas

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 21 papers. Top paper: “Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer”.

Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer

Journal of Clinical Medicine(2022)10.3390/jcm11051429

N/A

0.524DataRank · unranked

32 citations

Leonidas Arvanitis, Jeremy Fricke, Rebecca Pharaon, Angel Ray Baroz, Michelle Afkhami +4 more

A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811)

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.02.009

N/A

0.494DataRank · unranked

26 citations

Jieling Miao, Mihaela Cristea, Allen Chen, Jacob Sands, Roy H. Decker +13 more

Spirituality in cancer patients on phase 1 clinical trials

Psycho-Oncology(2020)10.1002/pon.5380

N/A

0.477DataRank · unranked

23 citations

Vincent Chung, Marianna Koczywas, Tami Borneman, Terry L. Irish, Nora Ruel +4 more

Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9014

N/A

0.373DataRank · unranked

11 citations

Mark Krailo, Sukhmani K. Padda, Susan Groshen, Heather A. Wakelee, Karen L. Reckamp +14 more

S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100738

N/A

0.241DataRank · unranked

4 citations

Ming-Hui Hsieh, Marianna Koczywas, Janet Tu, Jonathan W. Riess, Tawee Tanvetyanon +8 more

Co-stimulatory and co-inhibitory Immune Markers in Solid Tumors With MET Alterations

Future Science OA(2020)10.2144/fsoa-2020-0159

N/A

0.165DataRank · unranked

2 citations

Jasmine A. McQuerry, Isa Mambetsariev, Rebecca Pharaon, Susan E. Yost, Jeremy Fricke +14 more

Phase I study of TRC102 in combination with cisplatin and pemetrexed in patients with advanced solid tumors/Phase II study of TRC102 with pemetrexed in patients with mesothelioma refractory to pemetrexed and cisplatin or carboplatin.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9055

N/A

0.104DataRank · unranked

1 citations

Paul Frankel, Jonathan W. Riess, Anthony B. El-Khoueiry, Liza C. Villaruz, Stephen Leong +5 more

Alterations in STK11 to limit response to immune checkpoint inhibitors in lung cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e21503

N/A

0DataRank · unranked

0 citations

Isa Mambetsariev, Rebecca Pharaon, Angel Ray Baroz, Dan Zhao, Erminia Massarelli +3 more

Validity of patient-reported outcomes to describe the symptom experience of patients enrolled on phase I clinical trials.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.12107

N/A

0DataRank · unranked

0 citations

Betty Ferrell, Nora Ruel, Marianna Koczywas, Vincent Chung, Thomas J. Smith +1 more

Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer

CHEST Journal(2021)10.1016/j.chest.2021.04.016

N/A

0DataRank · unranked

44 citations

Isa Mambetsariev, Rebecca Pharaon, Jeremy Fricke, Hatim Husain, Karen L. Reckamp +5 more

The Association between Polluted Neighborhoods andTP53-Mutated Non–Small Cell Lung Cancer

Cancer Epidemiology Biomarkers & Prevention(2021)10.1158/1055-9965.epi-20-1555

N/A

0DataRank · unranked

21 citations

Sam E. Wing, Jenny Shen, Hengrui Hu, Ernesto Sosa, Lisa Lopez +19 more

A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013

Journal of Patient-Reported Outcomes(2020)10.1186/s41687-020-00220-x

N/A

0DataRank · unranked

5 citations

Joseph M. Unger, James L. Wade, Lynne I. Wagner, Mario E. Lacouture, Keisha C. Humphries +15 more

Role of immunotherapy and co-mutations on KRAS-mutant non- small cell lung cancer survival

Journal of Thoracic Disease(2020)10.21037/jtd.2020.04.18

N/A

0DataRank · unranked

46 citations

Isa Mambetsariev, Rohan Gupta, Srisairam Achuthan, Yingyu Wang, Rebecca Pharaon +5 more

Patient-defined goals and preferences among adults with advanced neuroendocrine tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.509

N/A

0DataRank · unranked

2 citations

Can‐Lan Sun, Heeyoung Kim, Christiana Crook, Yahan Zhang, Rebecca S. Allen +10 more

Impact of the Cancer and Aging Research Group (CARG) chemotherapy toxicity (tox) risk score on the benefit of a geriatric assessment–driven intervention (GAIN) among older adults with cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.28_suppl.235

N/A

0DataRank · unranked

0 citations

Can‐Lan Sun, Heeyoung Kim, Enrique Soto‐Pérez‐de‐Celis, Vincent Chung, Marianna Koczywas +13 more

Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer

Science Advances(2023)10.1126/sciadv.ade3816

N/A

0DataRank · unranked

68 citations

Arin Nam, Saumya Srivastava, Jeff Jones, Brett Lomenick, Sharad S. Singhal +30 more

Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy

Frontiers in Oncology(2023)10.3389/fonc.2023.1064169

N/A

0DataRank · unranked

14 citations

Isa Mambetsariev, Kun‐Han Lu, Chi Wah Wong, Ashley Duche, Richard Beuttler +10 more

Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma

Lung Cancer(2024)10.1016/j.lungcan.2024.107928

N/A

0DataRank · unranked

16 citations

Jun Vivien Yin, Penelope A. Bradbury, David J. Kwiatkowski, Shiven B. Patel, Lyudmila Bazhenova +24 more

A randomized trial of a palliative care intervention for patients on phase I studies.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.12001

N/A

0DataRank · unranked

4 citations

Vincent Chung, Mark T. Hughes, Marianna Koczywas, Nilofer S. Azad, Louise Knight +4 more

Precision medicine and actionable alterations in lung cancer: A single institution experience

PLoS ONE(2020)10.1371/journal.pone.0228188

N/A

0DataRank · unranked

9 citations

Yingyu Wang, Chen Chen, Sorena Nadaf, Rebecca Pharaon, Jeremy Fricke +19 more

Evaluation of immune-related adverse events in patients treated with sequential immunotherapy and tyrosine kinase inhibitor treatment in non-small cell lung cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e21562

N/A

0DataRank · unranked

0 citations

Isa Mambetsariev, Jeremy Fricke, Rebecca Pharaon, Dan Zhao, Marianna Koczywas +3 more